Acute toxicity of ADB‐CHMINACA ‐ a case series of patients with pronounced central nervous symptoms including the posterior reversible encephalopathic syndrome
Open Access
- 31 March 2026
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
Abstract
Aim: This report presents a series of 16 patients who were admitted to the emergency department following confirmed intake of the potent synthetic cannabinoid ADB‐CHMINACA. Methods: The cases are drawn from a prospective observational study following the recreational use of synthetic cannabinoids. The clinical and analytical data were combined and submitted to a Poison Centre. The severity of poisoning was evaluated on the basis of clinical data, including follow‐up information. The present analysis was conducted exclusively on patients with analytically confirmed intake of ADB‐CHMINACA and treatment in emergency departments for acute adverse effects. Cases with additional relevant serum concentrations of other drugs of abuse that suggested relevant interactions were excluded. Results: Common clinical manifestations included panic attacks, tachycardia, agitation, vomiting and seizures. Most of the patients experienced these symptoms within minutes after inhaling this new psychoactive substance. Serum concentrations of ADB‐CHMINACA varied widely and ranged from 0.2–31 ng/mL, without a clear correlation between severity of the poisoning and drug concentration. Severity of poisoning was moderate to severe, but all patients recovered. Notably, 1 of the patients developed a posterior reversible encephalopathy syndrome, a rare but serious neurological complication characterised by usually transient symptoms like headaches, seizures and altered mental state, often accompanied by brain oedema. In this case, the patient recovered after 4 days. Conclusion: Clinical presentations exhibited by patients with analytically confirmed intake of ADB‐CHMINACA showed similarities to previous reports; neuropsychiatric and cardiovascular symptoms were most prominent. Notable distinctions include the prevalence of panic attacks and trembling.Keywords
This publication has 24 references indexed in Scilit:
- ADB‐HEXINACA—a novel synthetic cannabinoid with a hexyl substituent: phase I metabolism in authentic urine samples, a case report and prevalence on the German marketDrug Testing and Analysis, 2024
- The identification of synthetic cannabinoids in English prisonsForensic Science International, 2023
- A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: Comparing prison and general populationsDrug Testing and Analysis, 2021
- Cumyl‐PEGACLONE: A comparatively safe new synthetic cannabinoid receptor agonist entering the NPS market?Drug Testing and Analysis, 2018
- Acute intoxication caused by synthetic cannabinoids 5F-ADB and MMB-2201: A case seriesForensic Science International, 2017
- Adverse effects after the use of JWH‐210 – a case series from the EU Spice II plus projectDrug Testing and Analysis, 2016
- Hyperthermia and severe rhabdomyolysis from synthetic cannabinoidsThe American Journal of Emergency Medicine, 2016
- Posterior reversible encephalopathy syndrome—Insight into pathogenesis, clinical variants and treatment approachesAutoimmunity Reviews, 2015
- Analysis of 30 synthetic cannabinoids in serum by liquid chromatography‐electrospray ionization tandem mass spectrometry after liquid‐liquid extractionJournal of Mass Spectrometry, 2012
- Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in ‘herbal mixtures’ using LC‐MS/MS techniquesJournal of Mass Spectrometry, 2012